uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology.
Show others and affiliations
2014 (English)In: British Journal of Dermatology, ISSN 0007-0963, E-ISSN 1365-2133, Vol. 170, no 1, 173-181 p.Article in journal (Refereed) Published
Abstract [en]


Oral liarozole, a retinoic acid metabolism-blocking agent, may be an alternative to systemic retinoid therapy in patients with lamellar ichthyosis.


To demonstrate the efficacy and safety of once-daily oral liarozole in the treatment of moderate/severe lamellar ichthyosis.


This was a double-blind, multinational, parallel phase II/III trial (NCT00282724). Patients aged >= 14 years with moderate/severe lamellar ichthyosis [ Investigator's Global Assessment (IGA) score >= 3] were randomized 3 : 3 : 1 to receive oral liarozole (75 or 150 mg) or placebo once daily for 12 weeks. Assessments included: IGA; a five-point scale for erythema, scaling and pruritus severity; Short Form-36 health survey; Dermatology Life Quality Index (DLQI); and safety parameters. The primary efficacy variable was response rate at week 12 (responder: >= 2-point decrease in IGA from baseline).


Sixty-four patients were enrolled. At week 12, 11/27 (41%; liarozole 75 mg), 14/28 (50%; liarozole 150 mg) and one out of nine (11%; placebo) patients were responders; the difference between groups (liarozole 150 mg vs. placebo) was not significant (P = 0.056). Mean IGA and scaling scores decreased from baseline in both liarozole groups at weeks 8 and 12 vs. placebo; erythema and pruritus scores were similar between treatment groups. Improvement in DLQI score was observed in both liarozole groups. Treatment with liarozole for 12 weeks was well tolerated.


The primary efficacy variable did not reach statistical significance, possibly owing to the small sample size following premature termination. However, once-daily oral liarozole, 75 and 150 mg, improved scaling and DLQI and was well tolerated in patients with moderate/severe lamellar ichthyosis.

Place, publisher, year, edition, pages
2014. Vol. 170, no 1, 173-181 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-218453DOI: 10.1111/bjd.12627ISI: 000329530200066OAI: oai:DiVA.org:uu-218453DiVA: diva2:695702
Available from: 2014-02-12 Created: 2014-02-12 Last updated: 2014-02-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Vahlquist, Anders
By organisation
Dermatology and Venereology
In the same journal
British Journal of Dermatology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 192 hits
ReferencesLink to record
Permanent link

Direct link